Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2, Observer Blinded, Controlled, Randomized Multi-Center Study in Adolescents, to Evaluate Safety, Tolerability and Immunogenicity of Four Different rMenB Plus MenACWY Formulations.

Trial Profile

Phase 2, Observer Blinded, Controlled, Randomized Multi-Center Study in Adolescents, to Evaluate Safety, Tolerability and Immunogenicity of Four Different rMenB Plus MenACWY Formulations.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 30 May 2014

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Meningococcal vaccine group B (Primary) ; Meningococcal vaccine groups A B C Y W-135 conjugate (Primary) ; Meningococcal vaccine groups A C Y W-135 conjugate
  • Indications Meningococcal group A infections; Meningococcal group B infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Novartis; Novartis Vaccines
  • Most Recent Events

    • 02 May 2012 Actual patient number of the extension trial (NCT01367158) changed from 456 to 440.
    • 02 May 2012 Status of the extension trial (NCT01367158) changed from recruiting to active, no longer recruiting.
    • 26 Dec 2011 Actual patient number amended from 480 to 456 as reported by ClinicalTrials.gov. (Extension trial: NCT01367158).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top